Status and phase
Conditions
Treatments
About
A combination of oral vitamin A (VitA) and intense aromatic chemosensory smell training (ST) by pulse aromatic stimulation will expedite the neurosensory recovery of olfaction in patients suffering from prolonged COVID-19-related olfactory dysfunction (OD).
Full description
This is an open-labeled randomised-controlled trial (RCT) investigating the safety and therapeutic efficacy of oral VitA in combination with ST for patients suffering from prolonged COVID-19-related OD.
Prior to the initiation of treatment, all patients will receive subjective and objective olfactory assessments. Comprehensive ear, nose, and throat (ENT) examination will be performed to rule out alternative causes of OD. All participants will receive resting-state functional magnetic resonance imaging (rs-fMRI) of the brain before treatment as baseline evaluation.
Patients with prolonged COVID-19-related OD will be assigned to the intervention (group A or B) or control (group C) arms:
Intervention arm A. 14-day course of daily oral VitA 7500µg RAE (retinol activity equivalents) in combination with ST three times per day for 4 weeks; or B. ST three times per day for 4 weeks alone; or
Control arm C. Observation
In addition, healthy controls who were tested negative for SARS-CoV-2 by reverse transcription polymerase chain reaction (RT-PCR) will receive rs-fMRI brain scans for radiological comparisons.
At the completion of the trial, subjective and objective olfactory assessments will be repeated to document clinical changes in olfaction. Follow-up rs-fMRI will be performed to document neuroradiological changes in the brain structures and cerebral network functional connectivity (FC).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Adult out-patient (≥18 years of age)
Previously diagnosed with coronavirus disease 2019 (COVID-19) by laboratory confirmation using reverse transcriptase polymerase chain reaction (RT-PCR) for the detection of severe acute respiratory virus coronavirus 2 (SARS-CoV-2)
Complaints of persistent olfactory disturbances, subjectively
Quantitatively documented to have olfactory dysfunction by
All subjects give written informed consent
Subjects must be available to complete the study and comply with study procedures.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
25 participants in 3 patient groups
Loading...
Central trial contact
Ivan Fan Ngai Hung, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal